Your browser doesn't support javascript.
loading
Características clínicas de la hepatotoxicidad asociada a la pirazinamida en pacientes de un hospital de Lima, Perú / Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru
Oscanoa, Teodoro; Moscol, Saul; Amado, José.
  • Oscanoa, Teodoro; Universidad de San Martín de Porres. Facultad de Medicina Humana. Centro de Investigación de Seguridad de Medicamentos. Lima. PE
  • Moscol, Saul; Hospital Nacional Guillermo Almenara Irigoyen. Servicio de Neumología. Lima. PE
  • Amado, José; Universidad Nacional Mayor de San Marcos. Facultad de Medicina. Lima. PE
Rev. peru. med. exp. salud publica ; 37(3): 516-520, jul-sep 2020. tab
Article in Spanish | LILACS | ID: biblio-1145024
RESUMEN
RESUMEN Con el objetivo de determinar las características de la enfermedad hepática inducida por el medicamento (DILI) se realizó un estudio de pacientes adultos con diagnóstico de tuberculosis y esquema de tratamiento antituberculoso con pirazinamida. El análisis de causa efecto de la DILI fue mediante el proceso de reexposición. Se encontraron 10 pacientes con DILI asociada a pirazinamida, la mediana de edad y de estancia hospitalaria fue de 40,5 años (rango 22-76) y 41 días (rango 11-130), respectivamente. La mediana de presentación del evento fue de 14 días (rango 3-46), 4 pacientes presentaron ictericia, 5 tuvieron patrón hepatocelular, 3 mixtas y 2 colestásicos. La presentación de la DILI fue leve en 6 casos (60%) y moderados en 3 (30%). En conclusión, la DILI asociada a la pirazinamida requiere estancia hospitalaria prolongada, se presenta con ictericia en un poco más de un tercio de los casos siendo el patrón predominante el hepatocelular.
ABSTRACT
ABSTRACT In order to determine the characteristics of drug-induced liver injury (DILI), adult patients diagnosed with tuberculosis and with an anti-tuberculosis treatment scheme including pyrazinamide were studied. The re-exposure process was used for the cause-effect analysis of the DILI. A total of 10 patients were found with pyrazinamide-associated DILI; the median age and hospital stay were 40.5 years (from 22 to 76 years) and 41 days (from 11 to 130 days), respectively. The median time in which the events appeared was 14 days (from 3 to 46 days); jaundice was observed in 4 patients and radiological patterns such as hepatocellular, mixed and cholestatic were found in 5, 3 and 2 patients, respectively. Mild presentation of DILI was observed in 6 cases (60%) and moderate in 3 (30%). In conclusion, pyrazinamide-associated DILI required prolonged hospital stay, presented jaundice in little more than a third of the cases, and radiologically, the hepatocellular pattern predominated.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Pyrazinamide / Tuberculosis / Antitubercular Agents Type of study: Risk factors Limits: Female / Humans / Male Country/Region as subject: South America / Peru Language: Spanish Journal: Rev. peru. med. exp. salud publica Journal subject: Public Health Year: 2020 Type: Article Affiliation country: Peru Institution/Affiliation country: Hospital Nacional Guillermo Almenara Irigoyen/PE / Universidad Nacional Mayor de San Marcos/PE / Universidad de San Martín de Porres/PE

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Pyrazinamide / Tuberculosis / Antitubercular Agents Type of study: Risk factors Limits: Female / Humans / Male Country/Region as subject: South America / Peru Language: Spanish Journal: Rev. peru. med. exp. salud publica Journal subject: Public Health Year: 2020 Type: Article Affiliation country: Peru Institution/Affiliation country: Hospital Nacional Guillermo Almenara Irigoyen/PE / Universidad Nacional Mayor de San Marcos/PE / Universidad de San Martín de Porres/PE